Peptide library
Bremelanotide
Approved product
Randomized evidence
Evidence record
- Product and route
- Subcutaneous injection.
- Approval scope
- Vyleesi: eligible premenopausal women with distressing acquired generalized low-desire disorder.
- Mechanism
- Melanocortin-receptor agonist.
- Evidence
- Randomized trials.
- Limits
- Exclude medical, relationship and drug causes; not performance enhancement.
- Safety context
- Uncontrolled hypertension or known cardiovascular disease: contraindicated.
A reading exercise
Draw a short timeline when checking a claim about bremelanotide. Mark the starting point, each stated observation time, and the point the claim asks you to imagine beyond them. Leave an empty space wherever no observation is supplied. Next, add a second line showing whose information is available at each point, if the source provides that detail. This separates a missing time interval from missing information about particular people. Try writing one question for each kind of gap. The aim is to keep the visible record and the page's proposed continuation distinct, rather than drawing a smooth line through unknowns.
Questions to take away
- Which part of the timeline has observations, and which part is only implied?
- Whose information is represented at the final observation time described by the source?
- What follow-up would answer the question left by the empty interval?
Sources
Each date identifies a source check. It is separate from this page’s publication date.
- VYLEESI — NLM; checked
- Kingsberg trials — PubMed; checked